Interestingly, S1P and S1PR1/3 agonists induced different degrees of hyperplasia and an increase of the prostate weight in vivo, while S1PR1/3 antagonist alleviated testosterone-induced BPH in vivo. The gene discussed is S1PR1; the disease is benign prostatic hyperplasia.